Form 4: Avanos Medical SVP, Chief Commercial Officer Kerr Holbrook Reports Transactions

Kerr Holbrook, SVP, Chief Commercial Officer of Avanos Medical, reports acquisition of restricted share units and employee stock options.

Summary

• On March 7, 2025, Kerr Holbrook, SVP, Chief Commercial Officer of Avanos Medical, acquired 22,877 shares of common stock at $0 and disposed of 98,860 shares.
• Holbrook also acquired 49,088 employee stock options with an exercise price of $15.24, exercisable from March 7, 2025, and expiring on March 7, 2035.
• The restricted share units (TRSUs) will vest in three equal installments on March 7, 2026, March 7, 2027, and March 7, 2028.
• The employee stock options will vest 30% on March 7, 2026, 30% on March 7, 2027, and 40% on March 7, 2028.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing showing compensation and transactions. The disposal of shares is slightly negative, but the acquisition of TRSUs and options balances it out.

Positives

• The acquisition of restricted share units and employee stock options suggests confidence in the company's future performance.

Negatives

• The disposal of 98,860 shares could be interpreted negatively, although the acquisition of TRSUs and options may offset this concern.

Risks

• Vesting of the restricted share units and employee stock options is contingent on continued employment and company performance.

Future Outlook

The vesting schedule of the restricted share units and employee stock options indicates a long-term incentive plan for the executive.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates the compensation structure for a key executive at Avanos Medical.

Comparison to Industry Standards

• Equity compensation, including stock options and restricted share units, is a common practice among publicly traded companies to align management's interests with those of shareholders.
• The vesting schedules described are typical for long-term incentive plans, designed to retain executives and incentivize long-term value creation.
• Comparing the size of the equity grants to those of executives at similar medical device companies (e.g., Medtronic, Stryker) would provide further context on the competitiveness of Avanos Medical's compensation practices.

Stakeholder Impact

• Shareholders can monitor insider transactions to gain insights into management's perspective on the company's prospects.
• Employees may be impacted by the company's overall performance, which influences the value of equity-based compensation.

Key Dates